Identification

Name
Nifedipine
Accession Number
DB01115  (APRD00590)
Type
Small Molecule
Groups
Approved
Description

Nifedipine has been formulated as both a long- and short-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nifedipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Nifedipine is used to treat hypertension and chronic stable angina.

Structure
Thumb
Synonyms
  • 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester
  • Adapine
  • Nifecard
  • Nifecor
  • Nifedipine
  • Nifedipino
  • Nifedipinum
  • Nifedipres
External IDs
BAY A 1040
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdalatCapsule5 mgOralBayer1997-01-072005-07-27Canada
Adalat - Cap 10mgCapsule10 mgOralBayer1982-12-312005-07-27Canada
Adalat Cap 10mgCapsule10 mgOralMiles Inc. Pharmaceutical Division1982-12-312000-08-01Canada
Adalat Cap 5mgCapsule5 mgOralMiles Inc. Pharmaceutical Division1986-12-312000-08-01Canada
Adalat CCTablet, film coated60 mg/1OralBayer1993-04-212017-11-14Us50419 0702 05 nlmimage10 531929c9
Adalat CCTablet, film coated90 mg/1OralAphena Pharma Solutions Tennessee, Inc.1993-04-21Not applicableUs
Adalat CCTablet, film coated90 mg/1OralALMATICA PHARMA INC.2017-02-01Not applicableUs
Adalat CCTablet, film coated30 mg/1OralALMATICA PHARMA INC.2016-10-25Not applicableUs
Adalat CCTablet, film coated30 mg/1OralBayer1993-04-212017-12-10Us50419 0701 05 nlmimage10 091904a8
Adalat CCTablet, film coated90 mg/1OralBayer1993-04-212017-11-14Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Afeditab CRTablet, film coated, extended release30 mg/1OralActavis Pharma Company2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release30 mg/1OralAphena Pharma Solutions Tennessee, Inc.2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release60 mg/1OralAphena Pharma Solutions Tennessee, Inc.2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release60 mg/1OralActavis Pharma Company2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release60 mg/1Oralbryant ranch prepack2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release30 mg/1OralCarilion Materials Management2002-11-01Not applicableUs00591 3193 01 nlmimage10 6d46b6f5
Apo-nifed PaTablet, extended release20 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-nifed PaTablet, extended release10 mgOralApotex Corporation1995-12-31Not applicableCanada
Dom-nifedipineCapsule10 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-nifedipineCapsule5 mgOralDominion PharmacalNot applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Adalat XL PlusNifedipine (20 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet, delayed release; Tablet, extended releaseOralBayer2008-07-242014-07-18Canada
Adalat XL PlusNifedipine (60 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet, delayed release; Tablet, extended releaseOralBayer2008-07-242014-07-18Canada
Adalat XL PlusNifedipine (30 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet, delayed release; Tablet, extended releaseOralBayer2008-07-242014-07-18Canada
International/Other Brands
Adalat / Adapine / Afeditab / Coracten / Nifecard / Nifecor / Nifedical / NifedicalXL / Nifedipres / Procardia
Categories
UNII
I9ZF7L6G2L
CAS number
21829-25-4
Weight
Average: 346.3346
Monoisotopic: 346.116486318
Chemical Formula
C17H18N2O6
InChI Key
HYIMSNHJOBLJNT-UHFFFAOYSA-N
InChI
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
IUPAC Name
3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC

Pharmacology

Indication

For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).

Structured Indications
Pharmacodynamics

Nifedipine, the prototype of the dihydropyridine class of calcium channel blockers (CCBs), is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, nifedipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives nifedipine additional arterial selectivity. At therapeutic sub-toxic concentrations, nifedipine has little effect on cardiac myocytes and conduction cells. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.

Mechanism of action

Nifedipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. The vasodilatory effects of nifedipine result in an overall decrease in blood pressure.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UCalmodulin
inhibitor
Human
UPotassium voltage-gated channel subfamily A member 1
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
Absorption

Rapidly and fully absorbed following oral administration.

Volume of distribution
Not Available
Protein binding

92-98%

Metabolism

Hepatic metabolism via cytochrome P450 system. Predominantly metabolized by CYP3A4, but also by CYP1A2 and CYP2A6 isozymes.

Route of elimination

Nifedipine is extensively metabolized to highly water-soluble, inactive metabolites accounting for 60 to 80% of the dose excreted in the urine. The remainder is excreted in the feces in metabolized form, most likely as a result of biliary excretion.

Half life

2 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include dizziness, drowsiness, nausea, severe drop in blood pressure, slurred speech, and weakness. LD50=494 mg/kg (orally in mice); LD50=1022 mg/kg (orally in rats)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nifedipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nifedipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Nifedipine.Vet Approved
AbirateroneThe serum concentration of Nifedipine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Acebutolol.Approved, Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Nifedipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Nifedipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nifedipine is combined with Aliskiren.Approved, Investigational
AlprenololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Alprenolol.Approved, Withdrawn
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Nifedipine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nifedipine.Approved
AmiodaroneThe metabolism of Nifedipine can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nifedipine.Approved
AmobarbitalThe metabolism of Nifedipine can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nifedipine.Approved, Investigational
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Nifedipine.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nifedipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nifedipine is combined with Amyl Nitrite.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Nifedipine.Approved, Investigational
ApalutamideThe serum concentration of Nifedipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nifedipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nifedipine.Approved
AprepitantThe serum concentration of Nifedipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Nifedipine.Approved, Investigational
ArotinololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Arotinolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nifedipine.Approved, Investigational
ArtemetherThe metabolism of Nifedipine can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Nifedipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Atenolol.Approved
AtomoxetineThe metabolism of Nifedipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Atorvastatin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe metabolism of Nifedipine can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Nifedipine.Experimental
BarbexacloneThe metabolism of Nifedipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nifedipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nifedipine.Approved
BefunololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nifedipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nifedipine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Nifedipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Nifedipine.Approved, Withdrawn
BetaxololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Betaxolol.Approved, Investigational
BevantololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bevantolol.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Nifedipine.Approved, Investigational
BisoprololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bisoprolol.Approved
BoceprevirThe metabolism of Nifedipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bopindolol.Approved
BortezomibThe metabolism of Nifedipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nifedipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nifedipine.Approved
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Nifedipine.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nifedipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Nifedipine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nifedipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nifedipine.Approved, Investigational
BucindololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bucindolol.Investigational
BufuralolThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nifedipine.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Nifedipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nifedipine.Approved, Investigational
BupranololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bupranolol.Approved
BupropionThe metabolism of Nifedipine can be decreased when combined with Bupropion.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Nifedipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Nifedipine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nifedipine.Approved
CaffeineThe metabolism of Nifedipine can be decreased when combined with Caffeine.Approved
Calcium AcetateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nifedipine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Nifedipine.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Nifedipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Captopril.Approved
CarbamazepineThe serum concentration of Nifedipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbamazepineThe metabolism of Nifedipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nifedipine.Approved, Investigational
CarteololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Carteolol.Approved
CarvedilolThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Nifedipine.Approved
CelecoxibThe metabolism of Nifedipine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nifedipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nifedipine.Approved, Withdrawn
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Nifedipine.Approved
ChloroquineThe metabolism of Nifedipine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Nifedipine.Approved
ChlorpromazineThe metabolism of Nifedipine can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nifedipine.Approved
CholecalciferolThe metabolism of Nifedipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Nifedipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nifedipine.Approved, Investigational
CimetidineThe serum concentration of Nifedipine can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Nifedipine can be decreased when combined with Cinacalcet.Approved
CisaprideThe serum concentration of Nifedipine can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Nifedipine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Nifedipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nifedipine can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clevidipine.Approved, Investigational
ClobazamThe metabolism of Nifedipine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nifedipine.Approved, Investigational
ClomipramineThe metabolism of Nifedipine can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nifedipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nifedipine.Approved
CloranololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Cloranolol.Experimental
ClotrimazoleThe metabolism of Nifedipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Nifedipine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Nifedipine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Nifedipine can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nifedipine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nifedipine.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nifedipine.Investigational
CrizotinibThe metabolism of Nifedipine can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Nifedipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Nifedipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nifedipine.Approved
DabrafenibThe serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dapagliflozin.Approved
DarifenacinThe metabolism of Nifedipine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nifedipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Nifedipine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Nifedipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nifedipine can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nifedipine.Approved
DesipramineThe metabolism of Nifedipine can be decreased when combined with Desipramine.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nifedipine.Approved, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Nifedipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Diclofenamide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nifedipine.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nifedipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nifedipine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nifedipine.Experimental
DihydroergotamineThe metabolism of Nifedipine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Nifedipine can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Nifedipine can be decreased when combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nifedipine.Approved
DosulepinThe metabolism of Nifedipine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Nifedipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nifedipine.Approved, Investigational
DoxycyclineThe metabolism of Nifedipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Nifedipine can be decreased when combined with Dronedarone.Approved
DuloxetineNifedipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Nifedipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nifedipine.Approved
EfavirenzThe serum concentration of Nifedipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Nifedipine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nifedipine.Approved, Investigational
EliglustatThe metabolism of Nifedipine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nifedipine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nifedipine.Approved
EnzalutamideThe serum concentration of Nifedipine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nifedipine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nifedipine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nifedipine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nifedipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nifedipine.Approved
ErythromycinThe metabolism of Nifedipine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nifedipine.Approved, Investigational
EthanolThe serum concentration of Nifedipine can be increased when it is combined with Ethanol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nifedipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nifedipine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Nifedipine.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nifedipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nifedipine.Approved, Investigational
FluconazoleThe serum concentration of Nifedipine can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Nifedipine.Approved, Investigational
FluoxetineThe serum concentration of Nifedipine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Nifedipine.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Nifedipine.Approved
FluvoxamineThe metabolism of Nifedipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nifedipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nifedipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.Approved
FosphenytoinThe serum concentration of Nifedipine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nifedipine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nifedipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nifedipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Nifedipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Nifedipine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nifedipine.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Nifedipine.Experimental
HaloperidolThe metabolism of Nifedipine can be decreased when combined with Haloperidol.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Nifedipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nifedipine.Approved, Vet Approved
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Nifedipine.Approved, Investigational
HexobarbitalThe metabolism of Nifedipine can be increased when combined with Hexobarbital.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nifedipine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nifedipine.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nifedipine.Approved
IdelalisibThe metabolism of Nifedipine can be decreased when combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Nifedipine.Approved, Investigational
ImatinibThe metabolism of Nifedipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nifedipine.Investigational
ImipramineThe metabolism of Nifedipine can be decreased when combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nifedipine.Approved
IndenololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Indenolol.Withdrawn
IndinavirThe metabolism of Nifedipine can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Nifedipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nifedipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nifedipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nifedipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Nifedipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nifedipine.Approved, Vet Approved
IsoniazidThe metabolism of Nifedipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nifedipine.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nifedipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Nifedipine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Nifedipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nifedipine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Nifedipine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Labetalol.Approved
LacidipineNifedipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Landiolol.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Nifedipine.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nifedipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nifedipine.Approved, Investigational
LevobunololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nifedipine.Approved, Investigational
LevodopaNifedipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nifedipine.Approved, Investigational
LidocaineThe metabolism of Nifedipine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Nifedipine.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Nifedipine.Approved, Investigational
LobeglitazoneThe metabolism of Nifedipine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Nifedipine.Approved, Investigational
LopinavirThe metabolism of Nifedipine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Nifedipine can be decreased when combined with Lorcaserin.Approved
LorpiprazoleThe serum concentration of Nifedipine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nifedipine.Approved
LovastatinThe metabolism of Nifedipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nifedipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nifedipine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Nifedipine can be decreased when combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nifedipine.Illicit, Investigational, Withdrawn
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nifedipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nifedipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nifedipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nifedipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Nifedipine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nifedipine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nifedipine.Approved, Investigational
MelatoninMelatonin may decrease the antihypertensive activities of Nifedipine.Approved, Nutraceutical, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Nifedipine.Experimental
MepindololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Mepindolol.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Nifedipine.Experimental
MethadoneThe metabolism of Nifedipine can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nifedipine.Approved
MethohexitalThe metabolism of Nifedipine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe metabolism of Nifedipine can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nifedipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nifedipine.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nifedipine.Approved
MethylphenobarbitalThe metabolism of Nifedipine can be increased when combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Nifedipine.Approved
MetipranololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nifedipine.Approved, Investigational
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Nifedipine.Experimental
MexiletineThe metabolism of Nifedipine can be decreased when combined with Mexiletine.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Nifedipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Nifedipine.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Nifedipine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Nifedipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Nifedipine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nifedipine.Approved, Investigational
MirabegronThe metabolism of Nifedipine can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Nifedipine can be decreased when it is combined with Mitotane.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nifedipine.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Nifedipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nifedipine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Nifedipine.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Nifedipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nifedipine.Approved, Investigational
NadololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Nadolol.Approved
NafcillinThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Nifedipine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nifedipine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Nifedipine.Approved
NebivololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Nifedipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nifedipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nifedipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Nifedipine can be decreased when it is combined with Nevirapine.Approved
NevirapineThe metabolism of Nifedipine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nifedipine can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Nifedipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Nifedipine.Approved, Investigational
NicotineThe metabolism of Nifedipine can be decreased when combined with Nicotine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Nifedipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Nifedipine.Investigational
NilotinibThe metabolism of Nifedipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Nifedipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nifedipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nifedipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nifedipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nifedipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nifedipine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nifedipine.Approved, Investigational
NitroprussideNifedipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Nifedipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Nifedipine.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Nifedipine.Approved, Investigational
OlaparibThe metabolism of Nifedipine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nifedipine.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Nifedipine.Experimental
OsimertinibThe serum concentration of Nifedipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Nifedipine.Approved
OxprenololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nifedipine.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nifedipine.Investigational
PalbociclibThe serum concentration of Nifedipine can be increased when it is combined with Palbociclib.Approved, Investigational
PanobinostatThe serum concentration of Nifedipine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nifedipine.Approved, Investigational
ParoxetineThe metabolism of Nifedipine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nifedipine.Approved
Peginterferon alfa-2bThe serum concentration of Nifedipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Penbutolol.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nifedipine.Approved, Investigational
PentobarbitalThe serum concentration of Nifedipine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentobarbitalThe metabolism of Nifedipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Nifedipine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nifedipine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nifedipine.Approved
PhenobarbitalThe serum concentration of Nifedipine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenobarbitalThe metabolism of Nifedipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nifedipine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Nifedipine.Approved
PhenytoinThe serum concentration of Nifedipine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nifedipine.Approved, Vet Approved
PindololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nifedipine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nifedipine.Approved
Platelet Activating FactorThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Platelet Activating Factor.Experimental
PosaconazoleThe metabolism of Nifedipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nifedipine.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nifedipine.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Nifedipine.Approved
PrimidoneThe serum concentration of Nifedipine can be decreased when it is combined with Primidone.Approved, Vet Approved
PrimidoneThe metabolism of Nifedipine can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Nifedipine can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nifedipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nifedipine.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Nifedipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifedipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nifedipine.Approved, Investigational
QuinineThe metabolism of Nifedipine can be decreased when combined with Quinine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Nifedipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nifedipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nifedipine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Nifedipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nifedipine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nifedipine.Approved, Investigational
RifabutinThe serum concentration of Nifedipine can be decreased when it is combined with Rifabutin.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Nifedipine.Approved, Investigational
RifampicinThe serum concentration of Nifedipine can be decreased when it is combined with Rifampicin.Approved
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Nifedipine.Approved
RifapentineThe serum concentration of Nifedipine can be decreased when it is combined with Rifapentine.Approved, Investigational
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Nifedipine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nifedipine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nifedipine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Nifedipine is combined with Riociguat.Approved
RisperidoneNifedipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Nifedipine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Nifedipine can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Nifedipine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nifedipine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Nifedipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Nifedipine.Approved
RucaparibThe metabolism of Nifedipine can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nifedipine.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nifedipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Nifedipine.Approved, Investigational, Vet Approved
SaquinavirThe metabolism of Nifedipine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nifedipine.Approved
SecobarbitalThe metabolism of Nifedipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Nifedipine.Approved, Investigational, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Nifedipine.Approved, Investigational
SertralineThe metabolism of Nifedipine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nifedipine.Approved, Vet Approved
SildenafilThe metabolism of Nifedipine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nifedipine.Approved
SiltuximabThe serum concentration of Nifedipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nifedipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Simvastatin.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Nifedipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Nifedipine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Nifedipine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Nifedipine.Approved
SotalolThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nifedipine.Approved
St. John's WortThe serum concentration of Nifedipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Nifedipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nifedipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nifedipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Nifedipine.Approved
SulfisoxazoleThe metabolism of Nifedipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nifedipine.Approved, Investigational
TalinololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Talinolol.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nifedipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Nifedipine.Approved, Investigational
TelaprevirThe metabolism of Nifedipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Nifedipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nifedipine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Nifedipine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Nifedipine.Approved
TerbinafineThe metabolism of Nifedipine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Nifedipine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Nifedipine.Experimental
TeriflunomideThe serum concentration of Nifedipine can be decreased when it is combined with Teriflunomide.Approved
TertatololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Tertatolol.Experimental
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nifedipine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Nifedipine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Nifedipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nifedipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nifedipine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Nifedipine.Approved
TiclopidineThe metabolism of Nifedipine can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Timolol.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Nifedipine.Approved
TipranavirThe metabolism of Nifedipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Nifedipine.Approved, Investigational
TocilizumabThe serum concentration of Nifedipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Nifedipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nifedipine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Nifedipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Nifedipine.Approved, Investigational, Vet Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nifedipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nifedipine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nifedipine.Approved
TranylcypromineThe metabolism of Nifedipine can be decreased when combined with Tranylcypromine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Nifedipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nifedipine.Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Nifedipine.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Nifedipine.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Nifedipine.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nifedipine.Approved, Investigational
VemurafenibThe serum concentration of Nifedipine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Nifedipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Nifedipine can be decreased when combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nifedipine.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Nifedipine.Approved, Investigational
VoriconazoleThe metabolism of Nifedipine can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Nifedipine can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Nifedipine can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Grapefruit down-regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take with low fat meal.

References

Synthesis Reference

Hiroitsu Kawata, Tadayoshi Ohmura, Katsuhiko Yano, Mikio Matsumura, Saburo Higuchi, Yoshiaki Soeishi, "Nifedipine-containing solid preparation composition." U.S. Patent US4412986, issued November, 1976.

US4412986
General References
  1. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366-72. [PubMed:10972368]
  2. Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, van Dalen FJ, Lubsen J: Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006 Feb;20(1):45-54. [PubMed:16552473]
  3. Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H: Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther. 2005 Apr;30(2):153-8. [PubMed:15811168]
  4. Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996 Oct 23-30;276(16):1328-31. [PubMed:8861992]
  5. Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, Gunduz MG, Safak C, Yamada S: Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol Pharm Bull. 2008 Mar;31(3):473-9. [PubMed:18310913]
  6. Varon J, Marik PE: Clinical review: the management of hypertensive crises. Crit Care. 2003 Oct;7(5):374-84. Epub 2003 Jul 16. [PubMed:12974970]
External Links
Human Metabolome Database
HMDB0015247
KEGG Drug
D00437
KEGG Compound
C07266
PubChem Compound
4485
PubChem Substance
46505103
ChemSpider
4330
BindingDB
50101817
ChEBI
7565
ChEMBL
CHEMBL193
Therapeutic Targets Database
DAP000529
PharmGKB
PA450631
IUPHAR
2514
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nifedipine
ATC Codes
C08CA05 — NifedipineC08CA55 — Nifedipine, combinationsC08GA01 — Nifedipine and diuretics
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (206 KB)
MSDS
Download (74.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentDermatomyositis / Lupus Erythematosus, Systemic / Raynaud Phenomenon Due to Trauma / Raynaud's Disease / System; Sclerosis / Ultrasound Therapy; Complications1
0RecruitingPreventionChronic Hypertension Complicating Pregnancy (Diagnosis) / Preeclampsia1
0RecruitingPreventionObesity, Morbid / Preeclampsia1
1Active Not RecruitingOtherHealthy Volunteers1
1CompletedNot AvailableBioavailability, Therapeutical Indication Not Studied1
1CompletedNot AvailableBioequivalence1
1CompletedNot AvailableDrug Dependence1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHypertension,Essential1
1CompletedBasic ScienceChronic Kidney Disease (CKD) / Proteinuria1
1CompletedTreatmentAcute iron intoxication / Hemochromatosis / Thalassaemic disorders1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1RecruitingTreatmentCytochrome P450 Interaction1
1, 2CompletedTreatmentCongenital Adrenal Hyperplasia (CAH)1
1, 2WithdrawnTreatmentHigh Blood Pressure (Hypertension) / Pregnancy Toxemias / Proteinuria1
2CompletedTreatmentAging / Cognitive Impairments / High Blood Pressure (Hypertension)1
2CompletedTreatmentChronic Kidney Disease (CKD) / CRD1
2CompletedTreatmentHypertension,Essential1
2CompletedTreatmentPlacenta Previa1
2CompletedTreatmentPremature Labour1
2RecruitingTreatmentImplantation, Embryo1
2Unknown StatusPreventionPremature Labour1
2Unknown StatusTreatmentBlood Pressures / Chronic Kidney Disease (CKD) / Proteinuria1
2, 3Active Not RecruitingTreatmentChronic Anal Fissures1
2, 3CompletedPreventionCerebral Palsy (CP) / Premature Labour1
2, 3RecruitingTreatmentHigh Blood Pressure (Hypertension)2
2, 3RecruitingTreatmentSevere Pre-Eclampsia, Antepartum1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Raynaud's Disease / Vascular Diseases1
3CompletedTreatmentHigh Blood Pressure (Hypertension)3
3CompletedTreatmentPulmonary Hypertension (PH)1
3Not Yet RecruitingTreatmentLabor Preterm Multiple1
3Not Yet RecruitingTreatmentPostnatal Hypertension1
3RecruitingTreatmentPremature Labour1
3TerminatedTreatmentPremature Labour1
3Unknown StatusTreatmentObstetric Labour, Premature1
3Unknown StatusTreatmentRenal Stones1
3WithdrawnTreatmentPreterm Delivery1
3WithdrawnTreatmentThreatened Preterm Labor1
4Active Not RecruitingPreventionMountain Sickness1
4CompletedBasic ScienceHigh Blood Pressure (Hypertension)1
4CompletedBasic SciencePremature Births1
4CompletedPreventionCoronary Artery Disease / Kidney Failure,Chronic1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedPreventionPremature Births1
4CompletedSupportive CareManaging Preterm Labor1
4CompletedTreatmentHigh Blood Pressure (Hypertension)6
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Other and unspecified effects of high altitude1
4CompletedTreatmentHypertension,Essential1
4CompletedTreatmentPremature Labour1
4RecruitingPreventionHypertension, Pregnancy-Induced / Prophylaxis of preeclampsia1
4RecruitingTreatmentHigh Blood Pressure (Hypertension)2
4RecruitingTreatmentHypertension in Pregnancy / Preeclampsia1
4RecruitingTreatmentPremature Labour2
4Unknown StatusTreatmentHypertension,Essential1
4Unknown StatusTreatmentUrinary Tract Stones1
Not AvailableActive Not RecruitingNot AvailablePremature Labour1
Not AvailableActive Not RecruitingTreatmentObstetric Labour, Premature1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)2
Not AvailableCompletedPreventionDiabetic Nephropathies1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Pregnancy / Prophylaxis of preeclampsia1
Not AvailableCompletedTreatmentObstetric Labour, Premature1
Not AvailableCompletedTreatmentObstetric Labour, Premature / Thrombosis, Venous1
Not AvailableCompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
Not AvailableCompletedTreatmentPremature Labour1
Not AvailableCompletedTreatmentSevere Postpartum Hypertension1
Not AvailableRecruitingNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableRecruitingBasic ScienceEndothelium, Vascular1
Not AvailableRecruitingTreatmentObstetric Labour, Premature1
Not AvailableTerminatedTreatmentPremature Births / Premature Labour1
Not AvailableTerminatedTreatmentPremature Labour1
Not AvailableWithdrawnTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableWithdrawnTreatmentLevator Ani Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral60 mg/1
Tablet, film coatedOral90 mg/1
TabletOral10 mg
TabletOral20 mg
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Kit; tablet, delayed release; tablet, extended releaseOral
Tablet, extended releaseOral60 mg/60mg
CapsuleOral10 mg
CapsuleOral10 mg/1
CapsuleOral20 mg/1
CapsuleOral5 mg
Capsule, liquid filledOral10 mg/1
Capsule, liquid filledOral20 mg/1
TabletOral30 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral60 mg/1
Tablet, extended releaseOral90 mg/1
Tablet, extended releaseOral10 mg
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Tablet, film coated, extended releaseOral90 mg/1
Prices
Unit descriptionCostUnit
Nifedipine powder15.3USD g
Procardia XL 90 mg 24 Hour tablet4.77USD tablet
Procardia xl 90 mg tablet4.58USD tablet
Procardia xl 60 mg tablet4.43USD tablet
Procardia XL 60 mg 24 Hour tablet4.13USD tablet
Adalat CC 90 mg 24 Hour tablet3.5USD tablet
Adalat cc 90 mg tablet3.37USD tablet
Adalat CC 60 mg 24 Hour tablet2.99USD tablet
Adalat cc 60 mg tablet2.87USD tablet
NIFEdipine CR Osmotic 90 mg 24 Hour tablet2.66USD tablet
Nifediac cc 90 mg tablet2.57USD tablet
Nifedipine er 90 mg tablet2.56USD tablet
Procardia xl 30 mg tablet2.56USD tablet
Procardia XL 30 mg 24 Hour tablet2.39USD tablet
NIFEdipine CR Osmotic 60 mg 24 Hour tablet2.38USD tablet
Nifedipine er 60 mg tablet2.29USD tablet
Afeditab cr 60 mg tablet2.24USD tablet
Nifediac cc 60 mg tablet2.17USD tablet
Adalat CC 30 mg 24 Hour tablet1.81USD tablet
NIFEdipine 20 mg capsule1.74USD capsule
Adalat cc 30 mg tablet1.61USD tablet
Adalat Xl 60 mg Extended-Release Tablet1.41USD tablet
NIFEdipine CR Osmotic 30 mg 24 Hour tablet1.35USD tablet
Adalat Xl 20 mg Extended-Release Tablet1.34USD tablet
Adalat Xl 30 mg Extended-Release Tablet1.34USD tablet
Nifedipine er 30 mg tablet1.32USD tablet
Afeditab cr 30 mg tablet1.26USD tablet
Mylan-Nifedipine Extended Release 60 mg Extended-Release Tablet1.18USD tablet
Procardia 10 mg capsule1.17USD capsule
Nifediac cc 30 mg tablet1.15USD tablet
NIFEdipine 10 mg capsule0.97USD capsule
Apo-Nifed 10 mg Capsule0.51USD capsule
Apo-Nifed 5 mg Capsule0.39USD capsule
Coral calcium plus 1500 mg caplet0.13USD caplet
Coral calcium 1000 mg caplet0.09USD caplet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5264446No1993-11-232010-11-23Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)172-174 °CPhysProp
water solubilityInsolubleNot Available
logP2.20MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0177 mg/mLALOGPS
logP2.49ALOGPS
logP1.82ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)5.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity92.16 m3·mol-1ChemAxon
Polarizability33.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9073
Blood Brain Barrier-0.9536
Caco-2 permeable+0.7853
P-glycoprotein substrateNon-substrate0.5089
P-glycoprotein inhibitor IInhibitor0.8771
P-glycoprotein inhibitor IIInhibitor0.7902
Renal organic cation transporterNon-inhibitor0.9182
CYP450 2C9 substrateNon-substrate0.7776
CYP450 2D6 substrateNon-substrate0.5726
CYP450 3A4 substrateSubstrate0.705
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.6122
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.6715
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9013
Ames testNon AMES toxic0.6973
CarcinogenicityNon-carcinogens0.5412
BiodegradationNot ready biodegradable0.9675
Rat acute toxicity2.5425 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.863
hERG inhibition (predictor II)Non-inhibitor0.903
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0v4i-1691000000-c4842fe2c3070d6e90dd

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines
show 6 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dihydropyridine (CHEBI:7565)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638]
  3. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Li GR, Deng XL, Sun H, Chung SS, Tse HF, Lau CP: Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells. 2006 Jun;24(6):1519-28. Epub 2006 Feb 16. [PubMed:16484345]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC: Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001 Feb;85(2):816-27. [PubMed:11160515]
  2. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:1990381...
Gene Name
KCNA1
Uniprot ID
Q09470
Uniprot Name
Potassium voltage-gated channel subfamily A member 1
Molecular Weight
56465.01 Da
References
  1. Bett GC, Rasmusson RL: Modification of K+ channel-drug interactions by ancillary subunits. J Physiol. 2008 Feb 15;586(4):929-50. Epub 2007 Dec 20. [PubMed:18096604]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Krasowski MD, Ai N, Hagey LR, Kollitz EM, Kullman SW, Reschly EJ, Ekins S: The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. BMC Biochem. 2011 Feb 3;12:5. doi: 10.1186/1471-2091-12-5. [PubMed:21291553]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. doi: 10.1124/dmd.110.032094. Epub 2010 Mar 4. [PubMed:20203109]
  2. Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA: Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther. 2005 Apr;313(1):302-9. Epub 2005 Jan 5. [PubMed:15634941]
  3. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Teng S, Jekerle V, Piquette-Miller M: Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. [PubMed:14570758]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118]
  3. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742]
  4. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]
  6. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  7. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Payen L, Sparfel L, Courtois A, Vernhet L, Guillouzo A, Fardel O: The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol Toxicol. 2002;18(4):221-33. [PubMed:12206135]

Drug created on June 13, 2005 07:24 / Updated on February 21, 2018 17:18